Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer

Journal of Clinical Oncology

Volumn 34, Issue 20, 2016, Pages 2325-2332

  Lee, W Robert ^a   Dignam, James J ^b,i   Amin, Mahul B ^c   Bruner, Deborah W ^f   Low, Daniel ^d   Swanson, Gregory P ^g   Shah, Amit B ^h   D'Souza, David P ^j   Michalski, Jeff M ^m   Dayes, Ian S ^k   Seaward, Samantha A ^e   Hall, William A ⁿ   Nguyen, Paul L ^o   Pisansky, Thomas M ^p   Faria, Sergio L ^l   Chen, Yuhchyau ^q   Koontz, Bridget F ^a   Paulus, Rebecca ⁱ   Sandler, Howard M ^c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e KAISER PERMANENTE   (United States)

^f EMORY UNIVERSITY   (United States)

^g SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^h York Cancer Center   (United Kingdom)

ⁱ NRG ONCOLOGY STATISTICS AND DATA MANAGEMENT CENTER   (United States)

^j London Regional Cancer Program   (United Kingdom)

^k MCMASTER UNIVERSITY   (Canada)

^l MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^m WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ MEDICAL COLLEGE OF WISCONSIN   (United States)

^o BRIGHAM AND WOMEN S HOSPITAL   (United States)

^p MAYO CLINIC   (United States)

^q UNIVERSITY OF ROCHESTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; CONTROLLED STUDY; CONVENTIONAL RADIOTHERAPY; DISEASE FREE SURVIVAL; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; HYPOFRACTIONATED RADIOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; THERAPY EFFECT; TREATMENT DURATION; TREATMENT INDICATION; UROGENITAL TRACT DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; MIDDLE AGED; MORTALITY; PROSTATIC NEOPLASMS; RADIATION DOSE FRACTIONATION; RADIATION INJURIES;

ADULT; AGED; DOSE FRACTIONATION; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RADIATION INJURIES;

EID: 84977517462     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.67.0448     Document Type: Article

References (29)

1. Swisher-McClure S, Mitra N, Woo K, et al: Increasing use of dose-escalated external beam radiation therapy for men with nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys 89:103-112, 2014
2. Fowler JF, Toma-Dasu I, Dasu A: Is the a/b ratio for prostate tumours really low and does it vary with the level of risk at diagnosis? Anticancer Res 33: 1009-1011, 2013
3. Kupelian PA, Willoughby TR, Reddy CA, et al: Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 68:1424-1430, 2007
4. Coote JH, Wylie JP, Cowan RA, et al: Hypofractionated intensity-modulated radiotherapy for carcinoma of the prostate: Analysis of toxicity. Int J Radiat Oncol Biol Phys 74:1121-1127, 2009
5. Ritter M, Forman J, Kupelian P, et al: Hypofractionation for prostate cancer. Cancer J 15:1-6, 2009
6. Aluwini S, Pos F, Schimmel E, et al: Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): Acute toxicity results froma randomised non-inferiority phase 3 trial. Lancet Oncol 16:274-283, 2015
7. Hoffman KE, Voong KR, Pugh TJ, et al: Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: Results from a randomized trial. Int J Radiat Oncol Biol Phys 88:1074-1084, 2014
8. Pollack A, Walker G, Horwitz EM, et al: Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol 31: 3860-3868, 2013
9. Arcangeli S, Strigari L, Gomellini S, et al: Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 84:1172-1178, 2012
10. Whelan TJ, Pignol JP, Levine MN, et al: Longterm results of hypofractionated radiation therapy for breast cancer. N Engl J Med 362:513-520, 2010
11. Edge S, Byrd DR, Compton CC, et al (eds): Cancer Staging Manual (ed 6). Chicago, IL, American Joint Committee on Cancer, 2002
12. Roach M III, Hanks G, Thames H Jr, et al: Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65:965-974, 2006
13. Lan KK, De Mets DL: Changing frequency of interim analysis in sequential monitoring. Biometrics 45:1017-1020, 1989
14. Fleming TR, Harrington DP, O'Brien PC: Designs for group sequential tests. Control Clin Trials 5:348-361, 1984
15. Kaplan EL, Meier P: Nonparametric-estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958
16. Korn EL, Dorey FJ: Applications of crude incidence curves. Stat Med 11:813-829, 1992
17. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
18. Prentice RL, Kalbfleisch JD, Peterson AV Jr, et al: The analysis of failure times in the presence of competing risks. Biometrics 34:541-554, 1978
19. Brenner DJ, Hall EJ: Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 43:1095-1101, 1999
20. Lee WR: Prostate cancer and the hypofractionation hypothesis. J Clin Oncol 31:3849-3851, 2013
21. Mohler JL, Kantoff PW, Armstrong AJ, et al: Prostate cancer, version 2.2014. J Natl Compr Canc Netw 12:686-718, 2014
22. Jones CU, Hunt D, McGowan DG, et al: Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 365: 107-118, 2011
23. Dearnaley D, Syndikus I, Sumo G, et al: Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: Preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol 13:43-54, 2012
24. Wilt TJ, Brawer MK, Jones KM, et al: Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 367:203-213, 2012
25. Kuban DA, Tucker SL, Dong L, et al: Long-term results of the M. D. Anderson randomized doseescalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70:67-74, 2008
26. Dearnaley DP, Jovic G, Syndikus I, et al: Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: Long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol 15:464-473, 2014
27. Michalski JM, Bae K, Roach M, et al: Longterm toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study. Int J Radiat Oncol Biol Phys 76:14-22, 2010
28. Kalbasi A, Li J, Berman A, et al: Doseescalated irradiation and overall survival in men with nonmetastatic prostate cancer. JAMA Oncol 1: 897-906, 2015
29. Cooperberg MR, Carroll PR: Trends in management for patients with localized prostate cancer, 1990-2013. JAMA 314:80-82, 2015